首页> 外文OA文献 >Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy.
【2h】

Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy.

机译:从CD4(pos)CD25(high)T细胞离体生成人同种抗原特异性调节性T细胞用于免疫治疗。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Regulatory T cell (Treg) based immunotherapy is a potential treatment for several immune disorders. By now, this approach proved successful in preclinical animal transplantation and auto-immunity models. In these models the success of Treg based immunotherapy crucially depends on the antigen-specificity of the infused Treg population. For the human setting, information is lacking on how to generate Treg with direct antigen-specificity ex vivo to be used for immunotherapy. METHODOLOGY/PRINCIPAL FINDINGS: Here, we demonstrate that in as little as two stimulation cycles with HLA mismatched allogeneic stimulator cells and T cell growth factors a very high degree of alloantigen-specificity was reached in magnetic bead isolated human CD4(pos)CD25(high) Treg. Efficient increases in cell numbers were obtained. Primary allogeneic stimulation appeared a prerequisite in the generation of alloantigen-specific Treg, while secondary allogeneic or polyclonal stimulation with anti-CD3 plus anti-CD28 monoclonal antibodies enriched alloantigen-specificity and cell yield to a similar extent. CONCLUSIONS/SIGNIFICANCE: The ex vivo expansion protocol that we describe will very likely increase the success of clinical Treg-based immunotherapy, and will help to induce tolerance to selected antigens, while minimizing general immune suppression. This approach is of particular interest for recipients of HLA mismatched transplants.
机译:背景:基于调节性T细胞(Treg)的免疫疗法是几种免疫疾病的潜在治疗方法。到目前为止,这种方法已证明在临床前动物移植和自身免疫模型中是成功的。在这些模型中,基于Treg的免疫疗法的成功关键取决于注入的Treg群体的抗原特异性。对于人类而言,缺乏有关如何在体外产生具有直接抗原特异性的Treg的信息,以用于免疫治疗。方法论/主要发现:在这里,我们证明了在低至两个HLA错配的同种异体刺激细胞和T细胞生长因子的刺激周期中,磁珠分离的人CD4(pos)CD25(高)Treg。获得有效的细胞数量增加。原发性同种异体刺激似乎是产生同种抗原特异性Treg的先决条件,而抗CD3加抗CD28单克隆抗体的继发性同种异体或多克隆刺激则以相似的程度丰富了同种异体抗原特异性和细胞产量。结论/意义:我们描述的离体扩增方案很可能会提高基于Treg的临床免疫疗法的成功率,并有助于诱导对选定抗原的耐受性,同时将总体免疫抑制降至最低。对于HLA错配移植的接受者,这种方法特别有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号